A
4.39
-0.25 (-5.39%)
| Previous Close | 4.64 |
| Open | 4.65 |
| Volume | 580,049 |
| Avg. Volume (3M) | 464,515 |
| Market Cap | 1,367,928,960 |
| Price / Earnings (TTM) | 19.09 |
| Price / Earnings (Forward) | 9.76 |
| Price / Sales | 2.39 |
| 52 Weeks Range | |
| Earnings Date | 18 Mar 2026 |
| Profit Margin | 16.42% |
| Operating Margin (TTM) | 7.97% |
| Diluted EPS (TTM) | 0.370 |
| Quarterly Revenue Growth (YOY) | 260.00% |
| Quarterly Earnings Growth (YOY) | -65.50% |
| Current Ratio (MRQ) | 1.73 |
| Operating Cash Flow (TTM) | -148.89 M |
| Levered Free Cash Flow (TTM) | -216.76 M |
| Return on Assets (TTM) | 7.02% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Alvotech | Bearish | Bearish |
AIStockmoo Score
-0.4
| Analyst Consensus | 1.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | -0.38 |
|
Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Growth |
| % Held by Insiders | 63.44% |
| % Held by Institutions | 6.44% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Lodbrok Capital Llp | 30 Sep 2025 | 181,587 |
| 52 Weeks Range | ||
| Median | 5.00 (13.90%) | |
| Total | 1 Sell | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Barclays | 09 Dec 2025 | 5.00 (13.90%) | Sell | 5.56 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |